Review of laquinimod and its therapeutic potential in multiple sclerosis

Bibliography

• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
   PubMed Web of Science ®Google Scholar
• Meuth SG, Göbel K, Wiendl H. Immune therapy of multiple sclerosis- future strategies. Curr Pharm Des 2012;18:4489-97
   PubMed Web of Science ®Google Scholar
• Methner A, Zipp F. Multiple sclerosis in 2012: novel therapeutic options and drug targets in MS. Nat Rev Neurol 2013;9:72-3
   PubMed Web of Science ®Google Scholar
• Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing remitting multiple sclerosis. Drugs 2013;73:625-50
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;16:183-200
   PubMed Web of Science ®Google Scholar
• Thöne J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol 2011;7:365-70
   PubMed Web of Science ®Google Scholar
• Brück W, Zamvil SS. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol 2012;5:245-56
   PubMed Web of Science ®Google Scholar
• Jansson K, Fristedt T, Olsson A, et al. Synthesis and reactivity of laquinimod, a quinolone-3-carboxamide: intramolecular transfer of the enol proton to a nitrogen atom as a plausible mechanism for ketene formation. J Org Chem 2006;71:1658-67
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Hallin I, Persson R, et al. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 2005;33:866-72
   PubMed Web of Science ®Google Scholar
• Brunmark C, Runström A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;30:163-72
   Web of Science ®Google Scholar
• Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in lewis rats. J Neuroimmunol 2004;156:3-9
   PubMed Web of Science ®Google Scholar
• Wegner C, Stadelmann C, Pförtner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demylination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;227:133-43
   PubMed Web of Science ®Google Scholar
• Zou LP, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002;42:731-9
   PubMed Web of Science ®Google Scholar
• Runström A, Leanderson T, Ohlsson L, Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006;173:69-78
   PubMed Web of Science ®Google Scholar
• Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013;136:1048-66
   PubMed Web of Science ®Google Scholar
• Gurevich M, Gritzman T, Orbach R, et al. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol 2010;221:87-94
   PubMed Web of Science ®Google Scholar
• Brück W, Pförtner R, Pham T, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 2012;124:411-24
   PubMed Web of Science ®Google Scholar
• Schulze-Topphoff U, Shetty A, Varrin-Doyer M, et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 2012;7:e33797
   PubMed Web of Science ®Google Scholar
• Thöne J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain derived neurotrophic factor. Am J Pathol 2012;180:267-74
   PubMed Web of Science ®Google Scholar
• Mishra MK, Wang J, Silva C, et al. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol 2012;181:642-51
   PubMed Web of Science ®Google Scholar
• Toubi E, Nussbaum S, Staun-Ram E, et al. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol 2012;251:45-54
   PubMed Web of Science ®Google Scholar
• Aharoni R, Saada R, Eilam R, et al. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2012;251:14-24
   PubMed Web of Science ®Google Scholar
• Centonze D, Muzio L, Rossi S, et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009;29:3442-52
   PubMed Web of Science ®Google Scholar
• Centonze D, Muzio L, Rossi S, et al. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 2010;17:1083-91
   PubMed Web of Science ®Google Scholar
• Rossi S, Muzio L, De Chiara V, et al. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 2011;25:947-56
   PubMed Web of Science ®Google Scholar
• Ruffini F, Rossi S, Bergamaschi A, et al. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler 2013;19:1084-94
   PubMed Web of Science ®Google Scholar
• Polman C, Barkhof F, Sandberg-Wollheim M, et al. Laquinimod in Relapsing MS Study Group. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64:987-91
   PubMed Web of Science ®Google Scholar
• Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92
   PubMed Web of Science ®Google Scholar
• Comi G, Abramsky A, Arbizu T, et al. Oral laquinimod in patients with relapsing–remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler 2010;16:1360-6
   PubMed Web of Science ®Google Scholar
• Comi G, Abramsky O, Arbizu T, et al. Long-term open extension of oral laquinimod in patients with relapsing multiple sclerosis shows favourable safety and sustained low relapse rate and MRI activity. Mult Scler 2009;15:P443
   PubMedGoogle Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Soelberg Sorensen P, Arnold DL. on behalf of the BRAVO Study Group. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis Amsterdam; 19 – 22 October 2011; The Netherlands
   Google Scholar